Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

October 31, 2015

Conditions
Anemia, Sickle CellSickle Cell AnemiaSickle Cell DiseaseSickle Cell DisordersHemoglobin SC DiseaseSickle Cell Hemoglobin C Disease
Interventions
DRUG

MP4CO

43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution

DRUG

Sodium chloride solution

Normal saline solution (0.9% Sodium Chloride Injection USP)

Trial Locations (14)

Unknown

Salmaniya Medical Complex, Manama

University Hospital Brugmann, Brussels

Rio de Janerio Instituto Estadual de Hematologie, Rio de Janerio

Hôpital Henri Mondor, Créteil

Georges Pompidou European University Hospital, Paris

American Univ. of Beirut Medical Center, Beirut

Univ. Medical Center Rizk Hospital, Beirut

Academic Medical Center, Amsterdam

Cornell Medical City, Doha

Cukurova University Medical Facilty, Adana

Mersin University Medical Faculty, Mersin

Guys Hospital, London

King's College Hospital, London

Queen Mary Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sangart

INDUSTRY